Ambulatorium Sp. z o.o.
- Address
- lock Available on a paid plan
Cardiovascular and Metabolic Research
At Ambulatorium Sp. z o.o. in Elblag, Poland, clinical trials in cardiovascular diseases and nutritional and metabolic diseases focus on major conditions such as atherosclerotic cardiovascular disease, chronic kidney disease, obesity, and overweight. These studies are designed to assess whether new therapies can reduce cardiovascular risk and support healthier weight management.
- Evaluating treatments aimed at lowering the risk of major cardiovascular events
- Studying therapies for obesity and overweight to improve body weight outcomes
- Investigating the link between kidney disease and broader cardiometabolic risk
This research area helps determine how emerging medicines may improve long-term heart and metabolic health in people with elevated risk.
Rheumatology and Musculoskeletal Studies
The site is active in musculoskeletal diseases and immune system diseases, with a strong emphasis on psoriatic arthritis, rheumatoid arthritis, osteoporosis, and related inflammatory joint conditions. These trials mainly explore new ways to reduce pain, stiffness, and disease activity while also comparing treatment effectiveness and safety.
- Testing therapies for psoriatic arthritis and active PsA
- Comparing biologic and biosimilar options for rheumatoid arthritis
- Studying bone health treatments in osteoporosis
This is a major research focus at Ambulatorium Sp. z o.o., supporting better control of chronic inflammatory and bone-related disorders.
Dermatology and Immune-Mediated Skin Disease
Clinical research in skin and connective tissue diseases and immune system diseases includes studies in moderate to severe plaque psoriasis and chronic spontaneous urticaria. The trials are aimed at finding treatments that can better control visible skin symptoms, reduce flare activity, and improve day-to-day comfort for patients.
- Assessing new options for plaque psoriasis
- Measuring symptom reduction in chronic spontaneous urticaria
- Exploring longer-term safety and tolerability of immune-targeted therapies
This area reflects a broader effort to improve care for persistent inflammatory skin conditions through more effective and durable treatment approaches.
Sjögren’s Disease and Autoimmune Research
The site also supports studies in immune system diseases and stomatognathic diseases, with attention to Sjögren’s disease and primary Sjögren’s disease. These trials are designed to evaluate whether new therapies can improve systemic disease activity and help address the burden of autoimmune symptoms.
- Investigating treatments for Sjögren’s disease
- Measuring changes in systemic disease activity
- Seeking better control of chronic autoimmune symptoms
This research supports the development of more targeted care for patients living with complex autoimmune conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 7 therapeutic areas and 15 of 19 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 7 by active trials.
- 1Eli Lilly & Co.2active
lock +6 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Eli Lilly & Co.5trials
lock +5 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Ambulatorium Sp. z o.o.
lock Showing 1 of 25 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis | MoonLake Immunotherapeutics AG | Phase III | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 19 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Zasocitinib | 5 | Unknown | 2024-05-07 | 2026-06-16 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.